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Stimulator of interferon genes (STING) has been
shown to be critical for controlling antiviral responses
as well as anti-tumor adaptive immunity, but little is
known regarding its regulation in human tumors.
Here, we report that STING signaling is recurrently
suppressed in a wide variety of cancers, including
colorectal carcinoma. Loss of STING signaling
impeded DNA damage responses accountable for
generating key cytokines that facilitate tissue repair
and anti-tumor T cell priming, such as type I inter-
ferons (IFNs). Correspondingly, defective STING
function was also highly predictive of effectual DNA-
virus-mediated oncolytic activity. Thus, impaired
STING responses may enable damaged cells to
evade host immunosurveillance processes, although
they provide a critical prognostic measurement that
could help predict the outcome of effective oncoviral
therapy.INTRODUCTION
Colorectal cancer (CRC) affects1.2 million people in the United
States, and 150,000 new cases are diagnosed every year.
Indeed, CRC is the third most common cause of cancer world-
wide, after lung and breast cancer, and the second leading cause
of cancer death in adults (DeSantis et al., 2014). Intestine-associ-
ated malignant disease frequently develops from colonic epithe-
lial cells that accumulate genetic alterations in key genes involved
in the control of cell growth (Fearon, 2011). Multistep genomic-
damage-aggravated alterations can be acquired from environ-
mental factors comprising carcinogens or from genotoxic micro-
bial pathogens, including Helicobacter pylori (Arthur et al., 2014;
Dzutsev et al., 2015; Kim and Chang, 2014; Louis et al., 2014).
Such genetic amendments frequently involve activation of cell
growth signaling throughmutation of k-ras aswell as throughmu-
tation or epigenetic silencing of critical tumor suppressor genes
(TSGs) such as p53 and adenomatous polyposis coli (APC).
Mutated TSGs such asAPCcan also be inherited, thus increasing
the riskofCRCsignificantly (Fearon,2011;Hammoudetal., 2013).282 Cell Reports 14, 282–297, January 12, 2016 ª2016 The AuthorsOrally administered carcinogens such as the DNA-adduct-
forming azoxymethane (AOM) induce genomic changes in
gastrointestinal epithelial cells, an event that can trigger the acti-
vation of DNA damage response (DDR) pathways (Chen and
Huang, 2009). While these responses involve repairing DNA
breaks and eliminating base mismatches, they can also include
activating the production of pro-inflammatory cytokines, which
alerts the immune surveillance system to the damaged area
and facilitates wound repair (Chatzinikolaou et al., 2014). For
example, using murine models, it has been demonstrated that
the administration of AOM followed by the inflammatory drug
dextran sulfate sodium (DSS) can cause epithelial cells to pro-
duce IL-1b and IL-18, which become processed by the inflam-
masome, a multiprotein complex comprising nucleotide-binding
oligomerization-domain protein-like receptors (NLRs) such as
NLRP3 and NLRP6, as well as apoptotic speck protein contain-
ing a CARD (ASC/PYCARD) and caspase-1, for secretion (Elinav
et al., 2013). IL-18, for example, can bind to colonic dendritic
cells and signal through MyD88 to prevent the production of
growth-inhibitory IL-22 binding protein (IL-22BP), which enables
unrestricted IL-22 to stimulate tissue repair (Huber et al., 2012;
Salcedo et al., 2010). Thus, mice defective in key inflamma-
some-associated molecules such as ASC or caspase-1 are sus-
ceptible to carcinogen-induced colitis-associated cancer (CAC)
(Elinav et al., 2013). Similarly, loss of key adaptor molecules such
as MyD88, required for IL1-R signaling, makes mice more sus-
ceptible to AOM/DSS-induced CAC (Salcedo et al., 2013). Plau-
sibly, unrepaired lesions enable the infiltration of microbes with
heightened genotoxic aptitude that can chronically aggravate in-
flammatory processes and the production of DNA-damaging
reactive oxygen species (ROS) (Arthur et al., 2012; Elinav et al.,
2013).
Although the inflammasome has been shown to be important
for processing proinflammatory cytokines such as IL-1b and IL-
18, it remained to be fully clarified how such wound repair pro-
teins become transcriptionally activated in response to actual
genomic damage. However, it has recently been shown that
mice lacking the innate immune regulator STING (stimulator of
interferon genes) are also sensitive to AOM/DSS-induced CAC
(Ahn et al., 2015; Ishikawa and Barber, 2008). STING resides in
the ER of hematopoietic cells as well as endothelial and epithelial
cells and controls the induction of numerous host defense
genes, such as type I IFNs, as well as pro-inflammatory genes,
including IL-1b, in response to the detection of cyclic
(legend on next page)
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dinucleotides (CDNs), such as cyclic di-AMP (c-di-AMP), gener-
ated from intracellular bacteria (Burdette et al., 2011; Ishikawa
et al., 2009). STING is also the sensor for CDNs produced from
a cellular nucleotidyltransferase referred to as cGAS (cyclic
GMP-AMP synthase, also referred to as Mab-21 domain-con-
taining protein and C6orf150) (Sun et al., 2013). Cytosolic DNA
species, which can constitute the genome of invading patho-
gens such as HSV-1, or plausibly self-DNA leaked from the
nucleus, can bind to cGAS to generate non-canonical cyclic
GMP-AMP (cGAMP) containing one 20-50 phosphodiester link-
age and a canonical 30-50 linkage (c[G(20,50)pA(30,50)p]) (Hornung
et al., 2014). The STING pathway may recognize damaged DNA
during early response to intestinal damage and may be essential
for invigorating tissue repair pathways involving IL-1b and IL-18
(Ahn et al., 2014a, 2015). STING has also been recently reported
to play an essential role in dendritic cell recognition of dying
tumor cells and the priming of anti-tumor cytotoxic T cell (CTL)
responses (Deng et al., 2014; Woo et al., 2014). Thus, while
loss of STING may facilitate tumorigenesis by preventing wound
repair and by preventing the production of tumor-specific CTLs,
the effectiveness of STING signaling in human tumors remains
unknown.
Here, we report that STING-mediated innate immune signaling
is largely impaired in human colon cancers as well as many other
types of human cancers. In many instances, this was achieved
through silencing STING and/or synthase cGAS expression
through epigenetic hypermethylation processes. Our findings
suggest that the STING pathway may have a major function in
suppressing colon tumorigenesis and that the inhibition of
STING function in this pathway may be selectively suppressed
during cancer development. However, we have found that de-
fects in STING signaling render cancer cells more susceptible
to oncolytic viral infection. Therefore, the examination of STING
activity in cancers may lead to development of assays that will
shed light on the outcome of select cancer therapies.
RESULTS
Defective STING Signaling in Colorectal
Adenocarcinoma Cells
STING-deficient mice have been reported to be prone to AOM/
DSS-associated CAC (Ahn et al., 2015). However, whether
STING function is deregulated to any extent in human colorectal
adenocarcinoma (CA) is unknown. To start to evaluate this, we
examined STING expression by immunoblot in a variety of CA
cells generated from cancers diagnosed at various stages as
described using Duke’s system (Wu, 2007). Results indicatedFigure 1. STING-Mediated dsDNA-Induced Innate Immune Activation I
(A) Immunoblot of STING in hTERT fibroblasts and normal human colon epithelia
(B) ELISA analysis of human IFN-b production in the media of cells (same as in A
(C) qPCR analysis of human CXCL10 expression in cells (same as in A) transfect
(D) qPCR analysis of human IL1b expression in cells (same as in C). Data are repre
0.05, **p < 0.01, and ***p < 0.001; Student’s t test.
(E) Microarray analysis of gene expression in indicated normal and colon cancer
variable genes are shown. Rows represent individual genes; columns represent in
to (black), or above (red) the mean. Scale represents the intensity of gene expres
(F) Fold-change values of the highest-variable genes shown in (E).
See also Figures S1 and S2.
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albeit at varying levels (Figure 1A). To correlate expression levels
with STING function, we transfected cells with double-stranded
DNA (dsDNA) to activate STING signaling, or with dsRNA
(poly(I:C)) to activate the RIG-I like pathway (Ishikawa and
Barber, 2008). We then measured type I IFN expression by
ELISA, which is known to be STING inducible. We noted that
all 11 CA cells responded poorly to dsDNA-triggered type I IFN
production. We confirmed that all cells were transfected
adequately using fluorescein isothiocyanate (FITC)-labeled
dsDNA activator and immunofluorescence analysis (Figure S1).
This was in contrast to control hTERT cells or normal colon
epithelial cells (FHC), which when transfected with dsDNA did
express IFN-b (Figure 1B). In contrast, 8 of the 11 CA cells
were able to produce type I IFN, in various amounts, in response
to dsRNA, indicating that the RIG-I-like pathway retained func-
tion in the majority of cases examined (Figures 1B and S2A). A
similar finding was noted upon examination of CXCL10 mRNA
production by RT-PCR, although some CXCL10 was detected,
albeit in low levels, in LoVo and HT29 in response to STING-
dependent dsDNA transfection (Figure 1C), whereas poly(I:C)
induced CXCL10 production in majority of CA cells at varying
degrees (Figure S2B). To extend these findings further, we
measured IL-1b production in the CA cells, since we have previ-
ously noted that carcinogen-triggered DNA damage can induce
IL-1b through STING signaling (Ahn et al., 2012). Loss of IL-1b
has been shown to render mice susceptible to CAC due to
impairment of wound-healing responses (Elinav et al., 2013).
This study indicated that IL-1b was produced in normal hTERT
and FHC cells by dsDNA, indicating the importance of STING ac-
tivity in this process. However, only 3 out of the 11 CA cells ap-
peared able to produce IL-1b in response to dsDNA treatment,
again suggesting that STING function is defective in the majority
of CA cells examined (Figure 1D). SW48, which lacked STING
expression, did not appear responsive to dsDNA transfection
in any capacity. RNAi treatment confirmed that the upregulation
of these cytokines was STING-dependent (Figures S3A–S3C).
Given these data, we performed a more detailed analysis of
dsDNA-dependent STING signaling in CA cells using microarray
analysis. CA cells were selected based on their ability to exhibit
some STING function or not. For example, data from Figure 1C
indicated that HT29 and LoVo cells were partially able to produce
CXCL10 in response to dsDNA. In contrast, SW480 and HT116
were noted to be unable to produce CXCL10 to any significant
level. Microarray analysis revealed that all the CA cells examined
did not respond to dsDNA signaling as efficiently as control FHC
cells and confirmed our RT-PCR analysis (Figures 1E and 1F).s Impaired in the Majority of Human Colon Cancer Cell Lines
l (FHC) and a series of human colon cancer cell lines.
) transfected with 3 mg/ml poly(IC) or dsDNA90 or mock transfected for 16 hr.
ed with 3 mg/ml dsDNA90 or mock transfected for 3 hr.
sentative of at least two independent experiments. Error bars indicate SD. *p <
cells mock transfected or transfected with 3 mg/ml dsDNA90 for 3 hr. Highest-
dividual samples. Pseudocolors indicate transcript levels below (green), equal
sion (log10 scale ranges between 3 and 3).
For instance, the level of CXCL10 was significantly higher in the
control FHC cells compared to the CA cells analyzed. However,
HT29 cells did appear to be able to retain some response to
cytosolic dsDNA, more than any of the other CA cells examined,
especially when compared to SW480 or HT116 (Figures 1E
and 1F). While HT29 was able to produce IFN-b moderately as
determined by microarray analysis, IFN-b protein production
was not readily evident by ELISA, perhaps due to low-level
expression, which was similarly observed even in the FHC con-
trols (Figure 1B). Nevertheless, taken together, our data indicate
that a majority of CA cells exhibit defective STING-dependent
signaling, with only SW1116, LS123, LoVo, and HT29 exhibiting
some low-level STING activity.
Loss of IRF3 Function in CA Cells
To examine the extent of defective STING signaling in CA cells,
we performed immunofluorescence and immunoblot analysis to
evaluate NF-kB and IRF3 function. In the presence of dsDNA,
STING rapidly undergoes trafficking from the ER, along with
TBK1, to perinuclear-associated endosomal regions, containing
NF-kB and IRF3, in a process resembling autophagy (Ishikawa
and Barber, 2008; Konno et al., 2013). This event accompanies
STING phosphorylation and degradation, likely to avoid sus-
tained STING-activated cytokine production, which can mani-
fest inflammation (Ahn and Barber, 2014). This approach
confirmed that STING could traffic and undergo phosphoryla-
tion and degradation in the control hTERT and FHC cells,
following treatment with dsDNA (Figures 2A and 2D, left). In
these cells, TBK1 became phosphorylated as well as its
cognate target IRF3 and the p65 subunit of NF-kB (Figure 2D,
left). IRF3 and p65 were also noted to translocate into the nu-
cleus, as expected (Figures 2B and 2C). A comparable effect
was observed using SW1116 and LS123 CA cells, which ex-
hibited modest dsDNA-dependent IL-1b induction, confirming
that the STING pathway retained some function in these two
cells (Figures 2A–2D, 1C, and 1D). However, while HT29 and
LoVo displayed similar IRF3 translocation, these cells lacked
p65 translocation. This likely helped to explain that the defect
in dsDNA-mediated innate immune gene induction rested in
the inability of STING to trigger p65 function (Figures 2A–2D,
1E, and 1F). In addition, we noted that the other CA cells,
such as SW480, SW1417, SW48, and HT116, exhibited very
little STING activity or trafficking (Figures 2A and 2D right). Simi-
larly, little evidence of TBK1 or IRF3 phosphorylation/transloca-
tion was noted (highlighted by red boxes). Some indication of
p65 phosphorylation was revealed, for example in SW480, but
translocation of this transcription factor was not evident in any
of the LoVo, HT29, SW480, SW48, SW1417, or HT116 cells.
In contrast, dsRNA induced IRF3 translocation in majority of
CA cells, although p65 translocation seemed to be impaired
to a larger extent (Figures S2C and S2D). STING expression
was not observed in SW48 cells as previously described (Fig-
ures 1A, 2A, and 2D). These data indicate that dsDNA signaling
is affected at various points of the STING pathway. For
example, STING retains some activity and ability to traffic and
escort TBK1 to IRF3, as in HT29 or LoVo cells, but NF-kB
signaling is affected. In contrast, STING does not appear to un-
dergo any phosphorylation or trafficking in SW480, SW1417,CSW48, or HT116 cells, suggesting that STING function is
impeded upstream of IRF3/NF-kB interaction.
CA Cells Exhibit Defective cGAS Expression
Loss of STING trafficking in SW480, SW1417, SW48, or HT116
cells could indicate a problem with STING function in the ER,
perhaps involving a mutation that would render STING unable
to interact with CDNs. Conversely, the breakdown in STING
signaling could occur upstream and involve the synthase
cGAS, which can generate CDNs following association with
dsDNA, to augment STING function (Konno et al., 2013). To eval-
uate this, we sequenced the entire STING genome within all 11
CA cells (introns and exons comprise 7.2 kb on chromosome
5q31.2). Sequence analysis indicated that 2 of the 11 CA cells
(LoVo and SW480) exhibited a previously reported HAQ STING
variant (Jin et al., 2011; Yi et al., 2013), which occurs in 20%
of the population, and which has been reported to be partially
defective when overexpressed in 293T cells, yet is able to func-
tion normally in the presence of CDNs (Table S1). The remainder
of the STING genes analyzed represented the R272 encoded
product, which has not been reported to exert any defects in
function and which represents 85% of the population. Collec-
tively, these findings do not suggest the existence of a major
mutation in the STING gene contained within the CA cells and
suggest that a defect upstream of STING, for example at the
level of cGAS, could plausibly be prevalent. We thus started to
examine the expression and activity of cGAS in CA cells. We
developed an RT-PCR assay and principally measured cGAS
mRNA levels. Our results indicated that, of the 11 CA cells exam-
ined, cGAS expression was absent in 5 (45%) of them (LS174T,
SW480, SW1417, SW48 and HT116) (Figure 3A). These data
were confirmed via immunoblot and immunohistochemistry
analysis using an antibody to cGAS (Figure 3A). A qPCR exami-
nation of 48 human colon adenocarcinoma samples similarly
indicated low to undetectable level of cGAS in 15 of 48 samples
(31%) (Figure S4). Our findings could be explained through loss
of the cGAS gene. However, sequencing analysis similarly indi-
cated that no major mutations or deletions existed within the
genome encoding the cGAS gene (Table S2). In view of this,
we examined whether cGAS expression was suppressed by
epigenetic phenomena, such as by hypermethylation of the
cGAS promoter region (Lao and Grady, 2011; Mitchell et al.,
2014). Indeed, databank analysis indicated the presence of
considerable CpG islands within the cGAS promoter region (Fig-
ure S5A). Control hTERT or cGAS-defective LS174T, SW480,
SW1417, SW48, or HT116 cells were thus treated with the deme-
thylating agent 5-aza-20-deoxycytidine (5AZADC) for 5 days, and
cGAS mRNA levels were again evaluated. Our study indicated
that cGAS expression was rescued in two of the five cells exam-
ined (SW480 and HT116) (Figure 3B). The sequencing of bisulfite
converted genomic DNA retrieved from normal and CA cells
confirmed significant hypermethylation within the cGAS pro-
moter region of CA cells where cGAS expression is suppressed
(Figure S5B). It is not yet clear why expression levels of cGAS are
muted in the remainder of the CA cells (LS174T, SW1417, and
SW48), but suppression could speculatively involve other epige-
netic modifications such as histone modifications (Jin and Rob-
ertson, 2013). Accordingly, treatment of these cells with histoneell Reports 14, 282–297, January 12, 2016 ª2016 The Authors 285
Figure 2. The dsDNA-Induced STING Signaling Pathway Is Defective in the Majority of Human Colon Cancer Cell Lines
(A) Immunofluorescence microscopy analysis of STING translocation in normal and human colon cancer cell lines transfected with 3 mg/ml dsDNA90 or mock
transfected for 3 hr.
(B) Immunofluorescence microscopy analysis of IRF3 translocation in cells (same as in A).
(C) Immunofluorescence microscopy analysis of p65 translocation in cells (same as in A). Representative images are shown at original magnification 1,2603.
Scale bar, 1 mm.
(D) Immunoblot analysis of STING signal activation in cells (same as above) transfected with 3 mg/ml dsDNA90 for the indicated time periods.
286 Cell Reports 14, 282–297, January 12, 2016 ª2016 The Authors
Figure 3. cGAS Expression Is Suppressed in Many Human Colon Cancer Cell Lines and Can Be Partially Recapitulated through DNA
Demethylation
(A) Immunoblot (top) and qPCR analysis (bottom) of cGAS expression in normal and human colon cancer cells.
(legend continued on next page)
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deacetylase or histone-lysine methyltransferases inhibitors par-
tially rescued cGAS mRNA expression in CA cells examined
(LS174T, SW1417, and SW48) (Figure S5C). It may also be
apparent that alternate mechanisms of cGAS suppression
exist, such as those involving microRNAs (miRNAs) (Yarbrough
et al., 2014). To determine if reconstitution of cGAS expression
rescued STING-dependent dsDNA signaling, we examined con-
trol hTERT or SW480, HT116 (cGAS rescued by 5AZADC), or
LS174T (cGAS not rescued by 5AZADC) CA cells. We observed
that the 5AZADC-treated cGAS-rescued SW480, HT116 CA
cells, but not LS174T cells, regained phosphorylation of TBK1
and IRF3, with concomitant phospho-IRF3 translocation (Fig-
ures 3C and 3D). These effects were reflected in modest expres-
sion of type I IFN and IL-1b in the 5AZADC-treated SW480 and
HT116 CA cells (Figures S5D and S5E). Thus, demethylating
agents may be able to partially rescue STING-dependent innate
immune gene induction in select CAs.
The question arises as to why the STING-signaling pathway
may be inhibited in colon adenocarcinoma. Recently, we have
shown that STING-deficient cells and mice are sensitive to
AOM-induced DNA damage (Ahn et al., 2015). In this situation,
the STING pathwaymay play a role in the DNA damage response
pathwayby inducing theproduction of cytokines that facilitate tis-
sue repair or damaged cell removal (Chatzinikolaou et al., 2014;
Kidane et al., 2014; Lord and Ashworth, 2012).We thus examined
innate immune induction of CA cells in response to DNA-
damaging agents. As shown in Figure 3E, the carcinogens AOM
and DMH (1,2-Dimethylhydrazine) were able to induce the pro-
duction of type I IFN in normal colon epithelial (CCD841) and in
LS123 (which exhibited partial STING activity; Figures 1C and
1D). However, CA cells that exhibited defective STING-activated
IRF3 or NF-kB activity were unable to generate type I IFN in
response to AOM or DMH (Figure 3E). Thus, the inhibition of the
STING pathway may enable DNA-damaged cells, harboring mu-
tations, to escape part of the DNA damage response and the im-
munesurveillancemachinery toprogress intoa tumorigenic state.
Tumors with Defective STING-Signaling Are Sensitive to
Viral Oncolysis
We have previously shown that loss of STING signaling in vitro or
in vivo renders cells or mice, respectively, extremely sensitive to
herpes simplex virus (HSV) infection (Ishikawa and Barber, 2008;
Ishikawa et al., 2009). HSV, containing a dsDNA genome of 375
kb, is presently being evaluated in clinical trials as a therapeutic
agent for the treatment of cancer (Kolodkin-Gal et al., 2009).
However, the mechanisms of oncolysis remain to be fully deter-
mined, and there is no evaluation, presently, for determining the
efficacy of HSV antitumor treatment. Given that we have previ-
ously shown that STING signaling plays a critical role in host de-(B) qPCR analysis of cGAS expression in cGAS-negative colon cell lines mock
representative of at least two independent experiments. Error bars indicate SD.
(C) Immunoblot analysis of STING signal activation in cells (selected from B) moc
dsDNA90 transfection at 3 mg/ml for the indicated time periods.
(D) Immunofluorescence microscopy analysis of IRF3 translocation in SW480
transfection at 3 mg/ml dsDNA90 for 3 hr. Representative images are shown at o
(E) Normal and colon cancer cells were treated with AOM or DMH at 3 mM for 2
See also Figures S3 and S4.
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defective in numerous CA cells, we postulated that the ability
of STING to signal may affect outcome to HSV oncoviral therapy.
To start to address this, we infected the CA cells or control
hTERT and FHC with HSV1 lacking the g34.5-encoding product
that is presently being evaluated as an oncolytic agent, including
against colon cancer as well as melanoma. The g34.5 viral pro-
tein has been proposed to suppress host defense responses,
although the mechanisms remain to be fully clarified. Thus,
HSV1g34.5 does not robustly repress innate immune signaling
events and potently triggers STING-dependent innate immune
gene induction, including type I IFNs (Ishikawa et al., 2009).
This analysis indicated that similar to our dsDNA transfection re-
sults, HSV1g34.5 induced the production of IFNb mRNA signifi-
cantly in control hTERT and FHC cells, as well as SW1116 and
LS123 CA cells (Figure 4A). However, little type I IFN was
induced in the remainder of the CA cells, including SW480 and
HT116, deficient in cGAS expression. The ability to induce type
I IFN inversely correlated with HSV1g34.5 replication, due to
the induced antiviral effects (Figure 4B). Furthermore, cells
such as SW480 and HT116 underwent rapid cell death, likely
due to robust viral replication, while control cells and cells with
partial STING function (SW1116 and HT29) were significantly
more refractory (Figure 4C). We followed up by infecting CA cells
with HSV expressing the luciferase gene that contained g34.5
(HSV-Luc). These data confirmed that CA cells exhibiting defec-
tive STING-signaling such as SW480 and HT116 enabled more
viral-induced luciferase expression (Figure 4D). Small interfering
RNA (siRNA) treatment further confirmed that the IFN-b re-
sponses induced by HSV1g34.5 in normal and STING functional
CA cells are STING dependent (Figure S3D). Of note is that HSV1
is not the only DNA virus to be considered as an oncolytic ther-
apeutic agent to treat cancer. Other candidate viruses under
consideration, including as a therapeutic against colon cancer,
comprise vaccinia virus (VV), a dsDNA virus with a 190-kb
genome that replicates in the cytoplasm of infected cells
(Rowe and Cen, 2014). To evaluate whether VV can trigger
host innate immune response in the absence of functional STING
signaling, we infected CA cells with partial STING signaling ca-
pacity (SW116 and HT29) or completely defective STING
signaling (SW480, HT116) with VV. Similar to the situation using
HSV1g34.5, VV triggered type I IFN and CXCL10 production only
in the control cells or CA cells with partial STING signaling ability
and not in cells with loss of STING function (SW480 and HT116)
(Figures 4E and 4F). We further analyzed CA cell susceptibility
of VV infection. As shown in Figures S6A–S6D, increased VV
replication and cell death were observed in all cells exhibiting
loss of cGAS or STING. Our data indicate that CA cells with
defective STING-signaling are highly susceptible to HSV1 andtreated or treated with 1 mM 5-azacytidine (5AZADC) for 5 days. Data are
*p < 0.05, **p < 0.01, and ***p < 0.001; Student’s t test.
k treated or treated with 1 mM 5-azacytidine (5AZADC) for 5 days, followed by
and HT116 cells treated with 5AZADC (same as above) followed by dsDNA
riginal magnification 1,2603. Scale bar, 500 nm.
0 hr. IFNb induction was analyzed by qPCR analysis.
Figure 4. STING Signal Defect Leads Colon
Cancer CellsMore Susceptible to DNAVirus
Infection
(A) Cells (same as in Figure 1) were infected with
HSV1g34.5 at MOI 5 for 1 hr, and human IFNb
induction was analyzed by qPCR 3 hr post-
infection.
(B) Normal human hTERT cells and selected hu-
man colon cancer cell lines (cGAS positive:
SW1116, HT29; cGAS negative: SW480, HT116)
were infected with HSV1g34.5 at the indicated
MOI for 1 hr, and titration of HSV1g34.5 was
analyzed by standard plaque assay in Vero cells
24 hr later.
(C) Cells (same as in B) were infected with
HSV1g34.5 at MOI 1 for 1 hr, and cell viability was
analyzed by trypan blue staining 24 hr and 48 hr
later.
(D) Cells (same as in A) were infected with HSV1-
Luc at the indicated MOI for 1 hr, and luciferase
activity was analyzed 24 hr later.
(E) Colon cancer cells were infected with vaccinia
virus at MOI 100 and analyzed by qPCR for IFNb
expression 3 hr postinfection.
(F) Cells (same as in E) were analyzed by qPCR for
CXCL10 expression.
Data are representative of at least two indepen-
dent experiments. Error bars indicate SD. *p < 0.05
and **p < 0.01; Student’s t test. See also Figure S2.VV oncolytic activity. Thus, it is plausible that being able to mea-
sure the presence or absence of STING/cGAS expression may
help predict the response of patients with certain cancers to
selected viral oncolytic therapy.
Predicting Outcome to Viral Oncolytic Therapy
Our data indicate that the outcome of oncolytic virotherapy
involving DNA-based viruses such as HSV1 may be predicted
by the presence or absence of STING signaling. Since the STING
pathway naturally requires the presence of STING and cGAS to
function, and since we have observed that STING and/or cGAS
may be absent in 30%–55% of colon cancers, being able to
measure the presence of these two gene products may therefore
indicate the effectiveness of DNA-viral oncotherapy. This could
be achieved using RT-PCR methodology, but biopsied tissue
may contain infiltrating hematopoietic cells that contain nor-Cell Reports 14, 282–297mal STING/cGAS expression (Ishikawa
et al., 2009). Thus, analysis of STING
and/or cGAS protein or RNA expression
within the cancer cell itself would provide
more accurate information into the status
of STING function. First, we designed a
RNA in situ hybridization assay using
RNAscope technology that can detect
the single levels copies of an mRNA
within individual cells. By labeling the
STING probe green (FITC), and the
cGAS probe red (Cy5), we were able to
use both probes in the same assay and
effectively quantitate the mRNA levels ofSTING and cGAS within the identical cell. To test the assay,
we incubated control cells or cGAS-positive (SW1116 or HT29)
or negative (SW480 and HT116) CA cells with RNA probes
recognizing cGAS (red) or STING (green) mRNA. This study indi-
cated that STING and cGAS expression could be detected and
quantitated in the control (hTERT and FHC) and STING/cGAS-
positive (SW1116 or HT29) CA cells using the RNAscope (Figures
5A and 5C). However, only STING was observed in the cGAS-
negative (SW480 and HT116) CA cells (Figures 5A and 5C).
STING was not detectable in SW48 cells, as expected, using
this assay (Figures 1A, 5A, and 5C). These data also correlated
with our previous expression analysis of cGAS in these cells by
RT-PCR (Figure 3A). Moreover, we were able to observe cGAS
expression by RNAscope in those CA cells where cGAS mRNA
production was rescued following treatment with 5AZADC
(SW480 and HT116) (Figures 5B and 5D). Thus, fluorescence, January 12, 2016 ª2016 The Authors 289
in situ hybridization analysis may be able to predict the outcome
to oncolytic viral therapy depending on the presence or absence
of cGAS or STING.
To further follow up on this assay, we paraffin embedded
normal hTERT or cGAS-positive (SW1116 or HT29) or negative
(SW480 and HT116) CA cells. We also analyzed SW48, in which
both cGAS and STING expression was missing. This situation
may mimic situations where biopsied and paraffin embedded
patient derived material required analysis. We were again readily
able to detect using the RNA probes both STING and cGAS
expression in control, SW1116, and HT29 cells, as before, and
only STING in the cGAS-negative SW480 and HT116 CA cells
(Figures 5E and 5F). Neither cGAS nor STING was observed in
the double-negative SW48 line (Figures 1A, 5E, and 5F). Using
antibody to cGAS and STING, we also performed immuno-
histochemistry (IHC) analysis on paraffin-embedded cells and
confirmed cGAS and STING expression, or not, in accord with
our immunoblot and RNAscope studies (Figures 1A, 3A, 5A,
5F, and 5G). Subsequently, we further tested our RNAscope
assay on 12 normal and 80 CA samples in paraffin-embedded
tissue microarrays (TMAs) and observed substantial loss of
STING and cGAS RNA expression starting from stage II. Overall,
36% (29 out of 80) cancer samples had undetectable STING
and/or cGAS RNA in stage II–IV colon cancer (Figures 6A and
6B). Furthermore, IHC analysis of a human colon cancer TMA
corroborated our RNA analysis and similarly showed substantial
loss of STING and/or cGAS protein expression starting predom-
inantly in stage II samples, generating an overall (stage II–IV) of
54% loss (21 out of 39) (Figures 6C and 6D). Statistical analysis
of STING and cGAS expression in different stages of colon can-
cer using the H-score method showed significant loss of cGAS
expression by IHC as early as stage II, whereas loss of STING
is more profound in later stages (Table S3). Given these data, it
is plausible that STING/cGAS expression is also lost in other tu-
mor types. Subsequently, we indeed noted that STING expres-
sion and/or function was absent in a variety of other tumor types,
indicating that suppression of this pathway may be widespread
in human cancer (Figure S7). In summary, RNAscope and IHC
procedures may be useful for the analysis of cGAS and STING
expression in formalin-fixed paraffin-embedded (FFPE) pre-
served samples.
In Vivo Analysis of CA Cells with Defective STING
Signaling to HSV1g34.5 Therapy
It is possible that loss of STING signalingmay affect the outcome
to select oncoviral therapy (Figures 4A–4D) (Kolodkin-Gal et al.,
2009; Rowe and Cen, 2014). To start to evaluate this in vivo, we
correlated the in vitro oncolytic effect of HSV1 by subcutane-
ously inoculating nude mice with CA cells harboring partial
(SW1116 or HT29) or defective (SW480 and HT116) STING
signaling. HSV1g34.5 was then administered intratumorally
and tumor growth monitored (Figure 7A). This study indicated
that tumors exhibiting partial STING signaling (SW1116 and
HT29) were refractory to viral oncolytic treatment (Figures 7B
and 7C). While these tumors had different growth rates in vivo,
they did not significantly respond to viral therapy, and the mice
were sacrificed after the tumor burden became significant. In
contrast, tumors derived from CA cells with defective STING290 Cell Reports 14, 282–297, January 12, 2016 ª2016 The Authorssignaling (SW480 and HT116) were noted to be extremely sus-
ceptible to virus treatment (Figures 7D and 7E). In mice im-
planted with SW480, tumor size decreased rapidly 3 days after
HSV1g34.5 treatment, and four out of seven tumors diminished
2–3 weeks after treatment (Figure 7D). In addition, we examined
the oncolytic effect of vaccinia virus in CA cells exhibiting partial
STING signaling (HT29) or completely defective in STING
signaling (HT116), and we observed that vaccinia virus reduced
the growth of HT116 in nude mice significantly (p = 0.012) when
compared to HT29 (p = 0.297) (Figures S6E and S6F). Our data
thus correlate with our in vitro findings and indicate that the ac-
tivity of the STING pathway may predict the outcome of DNA vi-
rus-related oncolytic therapy against colon and perhaps other
cancers.
DISCUSSION
The STING-controlled signaling pathway is essential for facili-
tating innate immune gene transcription in response to the
recognition of cytosolic DNA species (Ishikawa and Barber,
2008). STING activity can be triggered by CDNs such as cyclic
di-AMP or cyclic di-GMP produced from intracellular bacteria
such as Listeria monocytogenes or by cyclic di-GMP-AMP
(cGAMP) manufactured by the synthase cGAS following associ-
ation with cytosolic dsDNA species (Burdette et al., 2011; Cai
et al., 2014). Such DNA can represent the genome of DNA
pathogens, such as HSV-1 or bacteria such as mycobacterium
tuberculosis, as well as self-DNA leaked from the nucleus of
DNA-damaged cells. STING-deficient mice, while viable, are
extremely sensitive to lethal infection by a variety of pathogens
(Ishikawa et al., 2009). However, chronic STING activity has
been shown to cause a diversity of autoinflammatory disease,
through the overproduction of pro-inflammatory cytokines (Ahn
and Barber, 2014). Indeed, inappropriate overstimulation of
STING has even been shown to aggravate inflammation driven
skin cancer (Ahn et al., 2014b). Recently, transient STING activity
has been shown to be essential for mediating the generation of
anti-tumor T cell responses (Woo et al., 2015). Data suggest
that STING, in professional antigen-presenting cells (CD8+ den-
dritic cells), becomes extrinsically activated by the DNA of
engulfed dying tumor cells, which results in the triggering of cy-
tokines such as type I IFNs, which facilitates cross-presentation
and CTL priming (Woo et al., 2014). Correspondingly, the thera-
peutic administration of CDNs, intratumorally, has been shown
to repress tumor growth, presumably by facilitating dendritic
cell-dependent CTL production (Corrales et al., 2015; Woo
et al., 2014). STINGmay also play a role in influencing the anti-tu-
mor effects of checkpoint inhibitors such as PD1, although the
mechanisms remain to be determined (Fu et al., 2015).
We have also recently demonstrated that STING-deficient
mice are susceptible to carcinogen-aggravated CAC; however,
STING-deficient cells are not highly susceptible to oncogenic
transformation (Ahn et al., 2015). In this situation, evidence
indicates that damaged DNA can trigger STING-intrinsic ac-
tivity, perhaps by leaking out of the nucleus or through other
mechanisms that remain to be clarified. Presumably, this
event would augment cytokine production that would attract
the immune system to the damaged cells (Ahn et al., 2014a,
Figure 5. RNA In Situ Hybridization and Immunohistochemistry Analysis of STING and cGAS in Human Colon Cancer Cell Lines
(A) RNA fluorescence in situ hybridization (RNA FISH) analysis of STING and cGAS expression in normal and human colon cancer cell lines. Representative
images are shown at 1,2603. Scale bar, 500 nm.
(legend continued on next page)
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2014b; Chatzinikolaou et al., 2014; Deng et al., 2014; Kidane
et al., 2014; Zhu et al., 2014). Eradication of such cells may
ensue, as well as the stimulation of cytokine- and growth-fac-
tor-dependent tissue repair. Data suggest that STING can trigger
the production of cytokines that facilitate wound repair in the gut,
such as IL-1b. Such cytokines are processed by nucleotide-
binding oligomerization-domain protein-like receptors (NLRs)
such as NLRP3 and NLRP6, which interact with inflamma-
some-associated ASC and caspase-1 to process IL-1b and
IL-18 (Elinav et al., 2013). These pro-inflammatory cytokines
are secreted and bind to receptors mainly requiring MyD88 for
signaling. IL-18 production can suppress IL-22BP, which is
responsible for inhibiting the wound-repair activity of IL-22
(Huber et al., 2012). Loss of ASC, caspase-I, MyD88, or
IL22BP can increase tumorigenesis in colitis-associated colon
cancer models, similar to loss of STING (Barker et al., 2011; Eli-
nav et al., 2013; Huber et al., 2012; Salcedo et al., 2010). STING
may therefore work in concert with inflammasome processing.
Thus, loss of STING suppresses tissue healing, and damaged
mucosal lining may enable the invasion and expansion of bacte-
ria with enhanced genotoxic ability, which would aggravate
STING-independent inflammatory responses (Ahn et al., 2015;
Arthur et al., 2012). The generation of ROS by overactive, infil-
trating immune cells may enhance DNA-damaging processes
and facilitate mutational inactivation of TSGs or the mutational
activation of growth stimulatory proteins such as k-ras (Fearon,
2011; Sosa et al., 2013). Thus, intrinsic STING signaling may
play a key role in preventing the development of cancer through
responding to DNA damage and alerting the immune surveil-
lance machinery (Chatzinikolaou et al., 2014; Kondo et al.,
2013). In addition, extrinsic STING activity in dendritic cells is
also required for the generation of anti-tumor CTLs (Corrales
et al., 2015; Woo et al., 2015). This places STING in a pivotal
role in the host anti-cancer defense arsenal in which intrinsic
STING activity facilitates clearance of pre-cancerous cells by
alerting the immune system and extrinsic STING signaling stim-
ulates anti-tumor T cell activity.
Given this, we analyzed the expression and regulation of
STING signaling in colon cancer and found frequent suppression
of STING activity. These events inhibited the production of DNA-
damage-dependent cytokine production, which may enable the
damaged cell to escape the attention of the immune surveillance
system. Such cells may evade eradication and further genetic
mutation eventsmay accrue to enhance the tumorigenic process
(Elinav et al., 2013; Kidane et al., 2014). The inhibition of STING
signaling was observed to mainly involve the suppression of
STING expression or of the synthase cGAS. We did not observe
significant mutation or deletion events involving the STING or(B) RNA FISH analysis of STING and cGAS expression in SW480 and HT116 moc
shown at 1,2603. Scale bar, 500 nm.
(C) Quantitation of STING and cGAS RNA copy number in (A).
(D) Quantitation of cGAS RNA copy number in (B).
(E) STING and cGAS expression in formalin-fixed paraffin-embedded (FFPE) norm
hybridization (RNA CISH). Quantitation of STING and cGAS RNA copy number
experiments. Error bars indicate SD. *p < 0.05, **p < 0.01, and ***p < 0.001; Stud
(F) Representative images of STING and cGAS RNA CISH analysis are shown at
(G) Immunohistochemistry analysis of cGAS and STING expression in colon can
292 Cell Reports 14, 282–297, January 12, 2016 ª2016 The AuthorscGAS genes but rather observed frequent transcriptional sup-
pression involving hypermethylation of the promoter regions.
We were able to partially rescue cytosolic DNA signaling using
demethylating agents, which regained cGAS expression in
some, but not other, CA cells. However, it remains unclear
whether the rescue of STING signaling in cancer cells may afford
better responses to anticancer agents. Further, that cGAS and in
some cases STING expression was not rescued by demethylat-
ing agents may indicate other forms of epigenetic silencing that
requires additional characterization. In other CA types, we
observed that the ability of STING to activate the transcription
factors NF-kB or IRF3 was impaired, by molecular mechanisms
that also remain to be determined. It is noteworthy that a number
of other genes involved in DNA repair, such as the mismatch
repair proteins MHS2 and MLH1 are also reported to be
frequently silenced in colon cancer (Chatzinikolaou et al., 2014;
Le et al., 2015; Lord and Ashworth, 2012). Thus, targeting the
DNA repair machinery maybe a common requirement in cancer
development. Collectively, we observed that STING-dependent
signaling was defective in numerous colon related tumors exam-
ined. This may indicate that suppression of STING function is
also a key obligation for the tumorigenic process.
Since loss of STING may be common in tumors and may even
predict outcome to anticancer therapy, we also developed as-
says to evaluate the expression levels of both STING and
cGAS. Loss of either of these two proteins appears to repress
cytosolic DNA-mediated innate immune signaling. Our ability
to measure STING and cGAS mRNA expression in situ and
STING protein expression using antibody enabled us to develop
a screen that indicated loss of one or other of these proteins in
over 40% of CAC. Such assays may be useful in predicting the
effective response rates of cancers to select therapeutic inter-
ventions. Further, recapitulating STING signaling in tumors, via
novel antitumor gene therapy approaches, might enable such
cells to reactivate host antitumor immunity.
Accordingly, we noticed that loss of STING signaling in CA
cells enabled the robust replication of DNA-based viruses such
as HSV1. Viruses such as HSV1 and vaccinia virus are presently
being used as oncolytic agents for the treatment of cancer (Ko-
lodkin-Gal et al., 2009; Rowe and Cen, 2014). Such viruses may
directly destroy the tumor cell by lysis as well as create a tumor
antigen source for engulfment by APCs for the generation of
CTLs (Woo et al., 2015). Data indicate that STING plays a key
role in both of these processes (Figure S8). However, the efficacy
of successful oncoviral therapy remains low for reasons that
remain unclear. Mainly, assays based on molecular insight
that may help predict treatment outcome have not been devel-
oped. This is because the molecular mechanisms that explaink treated or treated with 1 mM 5 AZADC for 5 days. Representative images are
al and human colon cancer cell lines was analyzed by chromogenic RNA in situ
are shown in bar graph. Data are representative of at least two independent
ent’s t test.
6003. Scale bar, 1 mm.
cer cells. Images are shown at 4003. Scale bar, 20mm.
Figure 6. RNA In Situ Hybridization Analysis in Colon Cancer Tissue Microarray
(A) RNACISHanalysis ofSTINGandcGASexpression ina humancolon cancerTMA.STINGand/or cGASexpression status in each tissue is summarized in the table.
(B) Representative images in (A) are shown at 4003. Scale bar, 20 mm.
(C) IHC analysis of STING or cGAS expression in a human colon cancer TMA. Expression status is summarized in the table.
(D) Representative images in (C) are shown at 2003. Scale bar, 50 mm.
See also Figure S5.
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Figure 7. Increased HSV1g34.5 Oncolytic Effect Was Observed in Colon Cancer Cells with Impaired STING Signal In Vivo
(A) Scheme of HSV1g34.5 treatment on a xenograft tumor in nude mice.
(B–D) The indicated xenograft tumors were generated in the right flank of nude BALB/cmice.When tumors reached0.5 cm in diameter, they were injected every
other day, for a total of three times (arrows), with 1E7 PFU HSV1g34.5 in 50 ml PBS (n = 7) or 50 ml PBS only (n = 3), and tumor growth was measured every other
day. Data are representative of two independent experiments. Statistical analysis was carried out comparing the two treatment groups at the last time point using
the unpaired Student’s t test. p values are as indicated.
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oncolysis in cancer cells rather than normal cells remains to be
fully appraised. Evidence suggests that innate immune signaling
pathways that exert antiviral activity may be defective in cancer
cells (Heiber and Barber, 2012). In a tumor cell, functional
intrinsic STING signaling would prevent efficient virus replication
and oncolysis. We propose that this impedes the effectiveness
of oncolytic activity. However, in cells lacking STING, greater on-
colytic activity is expected and indeed observed and greater
cytolysis occurs, as our data show. This would provide a larger
amount of tumor cell lysate that would be engulfed and cross-
presented for T cell priming (which requires STING). Our data
presented here are among the first clear indication that loss of
an innate signaling pathway can predict outcome to oncoviral
therapy. Thus, utilization of molecular biomarker assays similar
to the ones portrayed here may enable a more predictive
response to the use of microbes for the treatment of cancer.
Such assays may also shed insight into whether other STING-
dependent anti-tumor therapies based on CDNs, or even DNA-
adduct based chemotherapeutic regimens, may work or not
(Zitvogel et al., 2013). In this light, we have recently described
that the immunological benefits of using chemotherapeutic
agents such as cisplatin and etoposide significantly involved
the STING-signaling pathway (Ahn et al., 2014b). Thus, further
studies on the regulation and function of STING in cancer may
provide acumen into the molecular mechanisms of tumorigen-
esis as well as provide a therapeutic target that may help in the
treatment of cancer.
EXPERIMENTAL PROCEDURES
Materials
All reagents were from Invitrogen, Thermo Scientific, or Sigma-Aldrich unless
otherwise specified.
Cell Culture
Cells were purchased from Lozna and ATCC and cultured in their appropriate
growth media. hTERT-BJ1 telomerase fibroblasts (hTERT) were originally from
Clontech and cultured in 4:1 ratio of DMEM:Medium 199 supplemented with
10% fetal bovine serum, 4 mM L-glutamine, and 1 mM sodium pyruvate at
37C in a 5% CO2-humidified atmosphere.
Immunoblot Analysis
Equal amounts of proteins were resolved on SDS-polyacrylamide gels and
transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). After
blocking with 5% blocking reagent, membranes were incubated with various
primary antibodies (and appropriate secondary antibodies). The image was
resolved using an enhanced chemiluminescence system ECL (Thermo Scien-
tific) and detected by autoradiography (Kodak). Rabbit anti-STING polyclonal
antibody was developed in our laboratory as described previously (Ishikawa
and Barber, 2008); other antibodies were obtained from following sources:
b-actin (Sigma-Aldrich), p-IRF3 (Cell Signaling), IRF3 (Santa Cruz Biotech-
nology), p-p65 (Cell Signaling), p65 (Cell Signaling), p-TBK1 (Cell Signaling),
TBK1 (Abcam), and cGAS (Cell Signaling).
Interferon-b ELISA Analysis
IFN-b ELISA was performed using either the IFN-b human ELISA kit from Invi-
trogen or the human IFN-b ELISA kit from PBL InterferonSource following the
manufacturer’s protocol.
Immunofluorescence Microscopy
Cell were fixed with 4% paraformaldehyde for 15 min in at 37C and permea-
bilized with 0.05% Triton X-100 for 5 min at room temperature. Immunostain-Cing was performed with STING, IRF3, or p65 antibody followed by fluores-
cence-conjugated secondary antibodies (FITC goat anti-rabbit) (Invitrogen).
Images were taken with a Leica LSM confocal microscope at the Image
Core Facility, University of Miami.
Microarray Analysis
Total RNAwas isolated from cells or tissueswith the RNeasyMini kit (QIAGEN).
RNA quality was analyzed using a Bionalyzer RNA6000Nano (Agilent Technol-
ogies). Gene array analysis was examined by Illumina Sentrix BeadChip Array
(Human HT-12_V4_Bead Chip) at the Oncogenomics Core Facility, University
of Miami. Gene expression profiles were processed and statistical analysis
was performed at the Bioinformatics Core Facility, University of Miami. Briefly,
raw intensity values from Illumina array are uploaded on GeneSpring software
from Agilent. Values are quantile normalized and log2 transformed to the me-
dian of all samples. Significantly differential expressed genes from a two-class
comparison are computed using the Student’s t test and selected using
threshold of p value % 0.05. Hierarchical clustering and visualization of
selected differentially expressed genes is performed on GeneSpring using
Pearson correlation distance method and linkage was computed using the
Ward method. Fold-change analysis was performed between two groups,
and differentially expressed genes were selected based on threshold of fold
changes.
Real-Time qPCR
Total RNAwas reverse transcribed using QuantiTect Reverse Transcription Kit
(QIAGEN). Real-time PCR was performed with the TaqMan gene Expression
Assay (Applied Biosystems).
Immunohistochemistry and Histological Analysis
Tissue microarray was purchased from Origene. Immunohistochemistry stain-
ing was performed with cGAS or STING antibody following standard protocol.
The score for the extent of the IHC-stained area was set as 0 for no IHC signal
at all, 1 for <10%, 2 for 10% to 50%, and 3 for >50%of tumor cells stained. The
score for IHC intensity was also scaled as 0 for no IHC signal, 1 for weak, 2 for
moderate, and 3 for strong. The final score used in the analysis was calculated
bymultiplying the extent score and intensity score, with amaximum score of 9.
Staining was considered positive if scoredR3.
Virus Amplification, Purification, Titration, and Infection
HSV-1 g34.5 was kindly provided by Bernard Roizman. HSV-1 luc was kindly
provided by David Leib. Vaccinia virus (vTF7-3) was kindly provided by John
Rose. Virus was amplified in Vero cells and purified by sucrose-gradient ultra-
centrifugation following standard protocol. Plague assay using serial diluted
virus was performed in Vero cells following standard protocol. Cells were in-
fected with virus at specific MOI for 1 hr, washed, and then incubated for
designated period for specific assay examination.
RNA In Situ Hybridization
The STING and cGAS RNA probe was custom designed by ACD, and RNA
in situ hybridization was performed using the RNAscope Multiplex Fluorescent
Reagent Kit for cultured cells and the 2-plex RNAscope Reagent Kit for FFPE
cells and tissue following the manufacturer’s instructions. Staining quantifica-
tion followed the score guideline, which was categorized into five grades: 0, no
staining or <1 dot in every 10 cells (403magnification); 1, 1–3 dots/cell (visible
at 20–403magnification); 2, 4–10 dots/cell and very few dot clusters (visible at
20–403magnification); 3, >10 dots/cell and <10%positive cells have dot clus-
ters (visible at 203magnification); and 4, >10 dots per cell and >10% positive
cells have dot clusters (visible at 203magnification). Staining was considered
positive if scoredR1.
Mouse Treatment
BALB/C nu/nu mice were purchased from Charles River and maintained in the
institutional Division of Veterinary Resources (DVR). All experiments were per-
formed with institutional animal care and use committee (IACUC) approval and
in compliance with IACUC guidelines. Tumor cells were introduced in the
flanks of BALB/c nude mice by subcutaneous injection of 2E6 of the appro-
priate tumor cells and tumors allowed to develop to an average diameter ofell Reports 14, 282–297, January 12, 2016 ª2016 The Authors 295
0.5 cm. HSV1g34.5 was then injected into the tumors every other day for a
total of three times at the appropriate dosage (i.e., 50 ml at 1E7 PFU/ml).
PBS was used as vehicle control. Effects on tumor growth were monitored.
Mice was euthanized when the tumor diameter exceeded 10 mm.
C57/BL6 wild-type (WT) or STING knockout (SKO) mice were injected sub-
cutaneously with B16-OVA tumor cells (5E105 cells/mouse) on day 0. On days
7, 9, and 11, mice were injected intratumorally with HSV1g34.5 (5E5 PFU/
mouse). PBS was used as control. Tumor volume was evaluated every other
day.
Interferon-g Assay
Splenocytes were isolated from WT or SKO mice inoculated with HSV1g34.5
(5E5 PFU/mouse) on day 13 after B16-OVA cell inoculation. The cells were
plated at 1E6 cells per well and stimulated with OVA peptide (SIINFEKL). After
48 hr, IFN-g levels were determined from the supernatant using amouse IFN-g
ELISA kit (R&D Systems) following the manufacturer’s instruction.
Bisulfite Sequencing Analysis
Bisulfite conversion of genomic DNA was performed using the EZDNAmethyl-
ation kit from Zymo Research followed by PCR amplification. PCR products
were then gel purified and Sanger sequenced.
Genomic DNA Sequencing
Genomic DNA was extracted from CA and normal cells using the QIAGEN
DNeasy kit, and the specific locus was sequenced by Polymorphic DNA
Technologies.
Statistical Analysis
All statistical analysis was performed by Student’s t test unless specified. The
data were considered to be significantly different when p < 0.05.
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